Ken Frazier, Merck CEO (Bess Adler/Bloomberg via Getty Images)

Mer­ck takes a swing at the IL-2 puz­zle­box with a $1.85B play for buzzy Pan­dion and its au­toim­mune hope­fuls

When Roger Perl­mut­ter bid farewell to Mer­ck late last year, the drug­mak­er per­haps best known now for sales gi­ant Keytru­da sig­naled its in­tent to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.